<DOC>
	<DOCNO>NCT01151787</DOCNO>
	<brief_summary>The primary objective study evaluate effectiveness safety cyclobenzaprine hydrochloride extend release ( Amrix 15mg/day ) prophylaxis chronic migraine compare placebo medication . A second objective , find whether improvement quality sleep self-reported depression patient take Amrix 15mg daily . The hypothesis number migraine day per month patient treat Amrix 15mg daily significantly low patient treat placebo .</brief_summary>
	<brief_title>Efficacy Safety Cyclobenzaprine Hydrochloride Extended Release Treatment Chronic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<criteria>1. male female , age 18 65 , headache longer 30 minute per day least 15 day per month ( 28 day ) meeting ICHDIIR criterion chronic migraine . Subjects must headaches least 8 day per month alleviate triptans ergots AND/OR least 1 migrainous feature ( unilaterality headache pain prominent 1 side head , throbbing , nausea , vomit , photophobia , phonophobia , increase pain physical exertion avoidance exertion ) 2. subject willing able perform studyrelated measure include accurately complete study diary instrument , maintain stable dos headache preventative medication , complete study visit obtain blood test indicate . 3. woman childbearing potential must use acceptable method birth control duration study ( oral contraceptive , IUD , injectable intravaginal contraception barrier method combine spermicide ) 1. subject &lt; 18 &gt; 65 year age 2. pregnancy attempt pregnancy study 3. nursing female 4. psychiatric condition , investigator 's opinion influence trial safety data collection 5. new daily persistent headache , hemicrania continuum , chronic tensiontype headache cluster headache diagnosis . 6. headache suspicious investigated rule secondary headache disorder 7. angle closure glaucoma 8. urinary retention 9. hepatic impairment felt investigator interfere study safety ( determined history and/or prerequisite liver function test within 1 year study enrollment ) 10. within 14 day MAO inhibitor use discontinuation 11. know hypersensitivity cyclobenzaprine hydrochloride component Amrix formulation 12. concomitant tramadol tricyclic antidepressant use 13. history myocardial infarction congestive heart failure 14. hyperthyroidism 15. new start daily preventative medication ( may influence headache ) less 2 month precede enrollment 16. dosage change discontinuation daily preventative medication ( may influence headache ) within 1 month trial enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>migraine</keyword>
</DOC>